key: cord-0775953-x8sd9epp authors: Giurgea, Luca T.; Morens, David M. title: Great Expectations of COVID-19 Herd Immunity date: 2022-01-25 journal: mBio DOI: 10.1128/mbio.03495-21 sha: bf56c443578e1e7951bf612cf17f00045dbbabd0 doc_id: 775953 cord_uid: x8sd9epp There is a common preconception that reaching an estimated herd immunity threshold through vaccination will end the COVID-19 pandemic. However, the mathematical models underpinning this estimate make numerous assumptions that may not be met in the real world. The protection afforded by vaccines is imperfect, particularly against asymptomatic infection, which can still result in transmission and propagate pandemic viral spread. Immune responses wane and SARS-COV-2 has the capacity to mutate over time to become more infectious and resistant to vaccine elicited immunity. Human behavior and public health restrictions also vary over time and among different populations, impacting the transmissibility of infection. These ever-changing factors modify the number of secondary cases produced by an infected individual, thereby necessitating constant revision of the herd immunity threshold. Even so, vaccination remains a powerful strategy to slow down the pandemic, save lives, and alleviate the burden on limited health care resources. immunity thresholds. Moreover, the herd immunity threshold formula relies on additional assumptions that are unlikely to hold in the case of COVID-19 due to its capacity to mutate, and to the nature of immune responses against nonsystemic respiratory viruses in general, which tend to be incomplete and transient (16) (17) (18) . Thus, herd immunity threshold estimates should be considered moving targets rather than biologically determined values. SARS-COV-2, like influenza, is an RNA virus with a high degree of plasticity in its spike protein (S) surface antigen (which elicits protective immune responses) and consequently a potential to rapidly mutate. Host adaptative mutations have been documented in viral variants of concern, including Alpha and Delta (19, 20) , which result in higher affinity binding of spike to the human angiotensin-converting enzyme 2 (ACE2) receptor, leading to higher mucosal viral loads and enhanced transmissibility (21, 22) . Updated estimates of the reproductive number for variants such as Alpha, Beta, and Gamma have been around 4.7-4.9 (21) , and around 5 for the Delta variant (22, 23) . Early estimates of Omicron's reproductive number are 4.2 times greater than estimates for Delta (24) . Hence, as variants with increasing R 0 values emerge, estimates for the herd immunity threshold will inevitably increase as well. In addition to host adaptational mutations, viruses have also developed numerous mutations that may allow them to evade host immune responses. Decreased binding of neutralizing antibodies (which are presumed to be correlates of protection) (25) from both convalescent COVID-19 patients and vaccinated individuals, to the Beta, Gamma, and Delta variants has been described (26, 27) , and vaccine efficacy has been lower in countries where the Beta and Gamma variants were more prevalent (3, 6) . This phenomenon is further exemplified with Omicron, which contains 32 S protein changes contributing to a 27-to 127-fold reduction in neutralization titers relative to wild-type SARS-COV-2. Not surprisingly, it has been spreading explosively in populations with high levels of vaccine-and natural infection-induced immunity (28) . While herd immunity threshold formulae assume robust and durable immunity, variants that evade population immunity can change estimates dramatically. Furthermore, waning of detectable anti-S, anti-receptor binding domain (RBD), and neutralizing antibody titers against COVID-19 over time, has occurred in the setting of natural and vaccineinduced immunity, with some half-life estimates ranging from 58 to 106 days (25, (29) (30) (31) . This is in contrast to immunity against other systemically-infecting respiratory viruses like measles. After recovery from infection, measles immunity is usually lifelong, associated with an estimated antibody half-life as high as 3,014 years (32) . Similarly, vaccination with a licensed live measles vaccine provides robust and durable immunity, lasting decades. However, this is not the case with COVID-19, where susceptibility to infection increases with increasing time since vaccination (33) (34) (35) . Therefore, estimates of herd immunity thresholds must account not only for partial vaccine efficacy but also changes in key parameters associated with a dynamic, mutating virus and with continuously waning immunity. Asymptomatic infection, which occurs in nearly one third of all COVID-19 cases (36), further complicates the ability to estimate vaccine efficacy and herd immunity thresholds because it perpetuates occult transmission. While an effective vaccine would protect against symptomatic disease, an ideal vaccine would prevent infection entirely, whether symptomatic or not. The effectiveness of COVID-19 vaccines in preventing asymptomatic infection, which may still be associated with transmission, is often lower and not well estimated (37, 38) . A retrospective study of health care workers who received the BNT162b2 vaccine determined that its effectiveness in preventing symptomatic disease was 97%, but only 86% in preventing asymptomatic infection (39) . Estimates from randomized trials are less optimistic: efficacy against asymptomatic disease of the mRNA-1273 vaccine was only 63% (compared to 93.2% against symptomatic illness), while the efficacy of the ChAdOx1 nCoV-19 vaccine was only 3.8% with the original dosing regimen (3, 40) . If the public health goal is to eradicate COVID-19 entirely, the effectiveness of vaccines in preventing both symptomatic and asymptomatic disease must be considered, since asymptomatic transmission in a pandemic setting can continue indefinitely. Finally, population heterogeneity must be considered: despite high overall theoretical population immunity, pockets of susceptible individuals can sustain viral circulation, as has been demonstrated with many other viruses including smallpox virus and polioviruses. Although more sophisticated mathematical models have attempted to address imperfect immunity and population heterogeneity (at least from the perspective of social interactions) (41) , it is important to consider that persistent circulation of virus in pockets of susceptible hosts can facilitate further mutation and eventually spark additional outbreaks after immunity wanes in the population at large, as seen with vaccine-derived polioviruses (42) . In short, mathematical estimates of R 0 and herd immunity thresholds may help guide public health responses but are likely to be poor predictors of epidemic reality and should not replace effective and adaptive public health responses against the evolving pandemic. Such conclusions are not surprising considering experience with other respiratory viruses. Serologic studies have demonstrated that the vast majority of the human population has been exposed to seasonal coronaviruses, endemic influenza virus strains, and other respiratory viruses like respiratory syncytial virus, but despite eliciting some degree of protective immunity, the viruses continue to circulate (43, 44) and reinfect individuals months or years after initial infection (17, 18, 45) . Vaccine approaches that induce more durable immunity and provide broader protection against future variants, so-called "universal vaccines" (46) , may alleviate some of the issues associated with herd immunity against respiratory viruses, but such vaccines are still under development. SARS-COV-2, like the descendants of the 1918 influenza pandemic, is undoubtedly here to stay. Indeed, all influenza pandemic strains since 1918 have established endemicity after their initial explosive spread. Fortunately, the presence of some degree of immunity against SARS-COV-2, even immunity that has waned over time or diminished in the face of viral escape mutations, may still provide protection against severe disease and save lives (47, 48) . Current vaccine strategies may be able to slow down SARS-CoV-2 spread and are likely to alleviate the burden that waves of severe cases can inflict on limited health care resources, but they are unlikely to lead to SARS-COV-2 eradication. Although herd immunity thresholds should not be thought of as precise biological parameters that can predict SARS-CoV-2 control, they may nevertheless have value in setting public health goals and in reminding us that our current pandemic control tools, when used aggressively, can reduce viral circulation, thereby saving lives and reducing illnesses and social-economic disruption. World Health Organization. 2021. WHO coronavirus (COVID-19) dashboard. World Health Organization C4591001 Clinical Trial Group. 2020. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Cove Study Group. 2021. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine Gam-COVID-Vac Vaccine Trial Group. 2021. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia ENSEMBLE Study Group. 2021. Safety and efficacy of singledose Ad26.COV2.S vaccine against Covid-19 Effectiveness of mRNA Covid-19 vaccine among U.S. Health Care Personnel Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile COVID-19 herd immunity: where are we? Herd immunity: understanding COVID-19 Vaccination and herd immunity to infectious diseases Feng Z. 2020. Early transmission dynamics in Population density and basic reproductive number of COVID-19 across United States counties Estimating the basic reproduction number for COVID-19 in Western Europe Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: A data-driven analysis in the early phase of the outbreak Occurrence and frequency of coronavirus infections in humans as determined by enzyme-linked immunosorbent assay Coronavirus occurrence in the HIVE cohort of Michigan households: reinfection frequency and serologic responses to seasonal and SARS coronaviruses Influenza A reinfection in sequential human challenge: implications for protective immunity and "universal" vaccine development SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity Differential Interactions between human ACE2 and spike RBD of SARS-CoV-2 variants of concern How will emerging SARS-CoV-2 variants impact herd immunity? The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus Confronting the Delta variant of SARS-CoV-2, summer 2021 Relative reproduction number of SARS-CoV-2 Omicron (B.1.1.529) compared with Delta variant in South Africa Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection Neutralizing activity of BNT162b2-elicited serum Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization Plasma neutralization of the SARS-CoV-2 Omicron variant Beigel JH, mRNA-1273 Study Group. 2021. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19 Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection Duration of humoral immunity to common viral and vaccine antigens Waning immunity after the BNT162b2 vaccine in Israel Phase 3 trial of mRNA-1273 during the Delta-variant surge Correlation of SARS-CoV-2 breakthrough infections to time-from-vaccine: preliminary study The proportion of SARS-CoV-2 infections that are asymptomatic: a systematic review Household transmission of SARS-CoV-2: a systematic review and meta-analysis SARS-CoV-2 transmission risk from asymptomatic carriers: results from a mass screening programme in Lancet Reg Health Eur 4:100056 Association between vaccination with BNT162b2 and incidence of symptomatic and asymptomatic SARS-CoV-2 infections among health care workers Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase A mathematical model reveals the influence of population heterogeneity on herd immunity to SARS-CoV-2 Vaccine-derived polioviruses Prevalence of antibodies to four human coronaviruses is lower in nasal secretions than in serum Prevalence of antibodies against seasonal influenza A and B viruses in children in Netherlands Seasonal coronavirus protective immunity is short-lasting Universal coronavirus vaccines: the time to start is now National Study Group for C-V. 2021. Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK This research was supported by the Intramural Research Program of the NIH.